Goldman Sachs
KZIA

Goldman Sachs’s Kazia Therapeutics KZIA Stock Holding History

Goldman Sachs’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-122
Closed -$98K – 7402
2015
Q2 		$98K Buy
+122
New +$138K ﹤0.01% 6626

Other funds holding KZIA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Goldman Sachs's KZIA Position: Q3 2015 in Review

Goldman Sachs sold out of Kazia Therapeutics (KZIA) in Q3 2015, closing a stake of 122 shares — an estimated $98K sold.

Goldman Sachs first reported a position in KZIA in Q2 2015 and held it in 1 quarter. The position peaked at $98K in Q2 2015. 7 funds tracked by Wall St. Rank hold KZIA as of Q3 2015.

  • Goldman Sachs reported no remaining Kazia Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Goldman Sachs sold 122 Kazia Therapeutics shares in Q3 2015, an estimated $98K.
  • Goldman Sachs first reported a position in Kazia Therapeutics in Q2 2015 and held it in 1 quarter.
  • Goldman Sachs's Kazia Therapeutics position peaked at $98K in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2015.

Based on Goldman Sachs's 13F filing for Q3 2015, filed 13 Nov 2015.